Keros Therapeutics (NASDAQ:KROS) VP Annita Tanini Sells 1,224 Shares

Keros Therapeutics, Inc. (NASDAQ:KROS) VP Annita Tanini sold 1,224 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total value of $12,594.96. Following the sale, the vice president owned 45,144 shares of the company’s stock, valued at $464,531.76. This represents a 2.64% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Keros Therapeutics Stock Down 1.4%

NASDAQ KROS traded down $0.15 during trading hours on Thursday, reaching $10.95. The company’s stock had a trading volume of 203,071 shares, compared to its average volume of 339,802. Keros Therapeutics, Inc. has a 1 year low of $9.69 and a 1 year high of $22.55. The company has a market capitalization of $217.14 million, a price-to-earnings ratio of -2.96 and a beta of 0.99. The firm’s 50-day moving average price is $10.67 and its 200-day moving average price is $11.90.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. Equities research analysts anticipate that Keros Therapeutics, Inc. will post -5.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on KROS. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Wells Fargo & Company reduced their target price on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a report on Tuesday, August 4th. Wall Street Zen downgraded shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday. Leerink Partners cut their target price on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Keros Therapeutics in a research report on Wednesday, August 12th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Keros Therapeutics has an average rating of “Hold” and a consensus price target of $20.50.

Hedge Funds Weigh In On Keros Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after purchasing an additional 1,166 shares during the period. Tower Research Capital LLC TRC lifted its stake in Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after acquiring an additional 1,888 shares during the period. Legal & General Group Plc bought a new stake in shares of Keros Therapeutics in the 2nd quarter valued at about $90,000. XTX Topco Ltd purchased a new stake in shares of Keros Therapeutics in the 4th quarter worth approximately $212,000. Finally, New York State Common Retirement Fund boosted its stake in shares of Keros Therapeutics by 264.1% during the second quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock valued at $142,000 after purchasing an additional 7,700 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-?) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.